UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2003

KINDRED HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-14057 (Commission File 61-1323993 (IRS Employer

of incorporation or organization)

Number)

Identification No.)

680 South Fourth Street

Louisville, Kentucky

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (502) 596-7300

Not Applicable

(Former name or former address, if changed since last report)

Item 9. Regulation FD Disclosure.

On August 12, 2003, the Company issued a press release announcing its financial results for the second quarter ended June 30, 2003. The press release, dated August 12, 2003, is attached as Annex A to this Item 9. On August 12, 2003, the Company also included the press release on its website at www.kindredhealthcare.com.

Annex A is incorporated herein by reference and has been furnished, not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

KINDRED HEALTHCARE, INC.

Date: August 12, 2003 By: /s/ Richard A. Lechleiter

Richard A. Lechleiter

Senior Vice President, Chief Financial

Officer and Treasurer

А	nney	А

[Kindred Logo appears here]

Contact: Richard A. Lechleiter Senior Vice President, Chief

Financial Officer and Treasurer

(502) 596-7734

KINDRED HEALTHCARE ANNOUNCES SECOND QUARTER RESULTS

Quarterly earnings from continuing operations totaled \$0.56 per diluted share

Company appoints Eddy J. Rogers, Jr. to Board of Directors

LOUISVILLE, Ky. (August 12, 2003) Kindred Healthcare, Inc. (the Company) (NASDAQ: KIND) today announced its operating results for the second quarter ended June 30, 2003. As a result of the Company s divestiture of all of its Florida and Texas nursing centers (the Florida and Texas Divestiture) on June 30, 2003, the consolidated results of operations of these facilities for all historical accounting periods and the loss related to the divestiture have been classified as discontinued operations.

Consolidated Results

For the second quarter of 2003, the Company reported a consolidated net loss of \$43 million or \$2.49 per diluted share. The net loss included income from continuing operations of \$10 million or \$0.56 per diluted share. The net loss also included a loss from discontinued operations of \$17 million or \$0.98 per diluted share and a loss from the Florida and Texas Divestiture aggregating \$36 million or \$2.07 per diluted share. For the three months ended June 30, 2002, the Company reported consolidated net income of \$24 million or \$1.21 per diluted share. Operating results for the second quarter of 2002 included income from continuing operations of \$28 million or \$1.40 per diluted share. Operating results for the second quarter of 2002 also included a loss from discontinued operations of \$4 million or \$0.19 per diluted share.

For the six months ended June 30, 2003, the Company reported a consolidated net loss of \$56 million or \$3.25 per diluted share. The net loss included income from continuing operations of \$10 million or \$0.55 per diluted share. The net loss also included a loss from discontinued operations of \$30 million or \$1.73 per diluted share and the previously discussed loss from the Florida and Texas Divestiture of \$36 million or \$2.07 per diluted share. For the six months ended June 30, 2002, the Company reported consolidated net income of \$42 million or \$2.16 per

diluted share. Operating results for the first six months of 2002 included income from continuing operations of \$49 million or \$2.51 per diluted share. Operating results for the first six months of 2002 also included a loss from discontinued operations of \$7 million or \$0.35 per diluted share.

Continuing Operations

Revenues in the second quarter of 2003 increased 4% to \$839 million compared to \$807 million in the second quarter of 2002. Income from continuing operations for the second quarter of 2003 totaled \$10 million or \$0.56 per diluted share compared to \$28 million or \$1.40 per diluted share in the year-earlier period. Operating results for the second quarter of 2003 included a benefit of approximately \$2 million or \$0.09 per diluted share resulting from a change in estimate of the Company s effective income tax rate for 2003. While each of the Company s business segments reported increased revenues, the decline in income from continuing operations was mostly attributable to the expiration of certain nursing center Medicare reimbursements on October 1, 2002 and increased professional liability costs primarily in the Company s nursing center business.

Provisions of the Balanced Budget Refinement Act (the BBRA) and the Medicare, Medicaid, and State Child Health Insurance Program Benefits Improvement and Protection Act of 2000 (BIPA) that expired in the fourth quarter of 2002 reduced Medicare revenues in the Company s nursing centers by approximately \$14 million in the second quarter of 2003 compared to the same period a year ago. Consolidated professional liability costs aggregated \$21 million in the second quarter of 2003 compared to \$9 million in the second quarter of 2002, of which approximately \$16 million and \$5 million, respectively, was charged to the Company s nursing center business. Professional liability costs recorded in the first quarter of 2003 approximated \$32 million (including a \$9 million charge for a change in estimate of prior year costs), of which \$25 million were charged to the Company s nursing center business.

Operating results for the second quarter of 2002 included income of approximately \$5 million (\$3 million net of income taxes) related to changes in estimates of accrued reorganization items and a lease termination charge for an unprofitable hospital.

For the six months ended June 30, 2003, revenues increased 5% to \$1.7 billion from \$1.6 billion in the first half of 2002. Income from continuing operations totaled \$10 million or \$0.55 per diluted share for the first six months of 2003 compared to \$49 million or \$2.51 per diluted share in the same period a year ago. The previously discussed reductions in nursing center Medicare reimbursement and increased professional liability costs primarily contributed to the decline in earnings.

Provisions of the BBRA and BIPA that expired in the fourth quarter of 2002 reduced Medicare revenues in the Company s nursing centers by approximately \$28 million for the first six months of 2003 compared to the same period a year ago. Professional liability costs aggregated \$53 million for the six months ended June 30, 2003 compared to \$17 million in the first six months of 2002, of which approximately \$41 million and \$10 million, respectively, were charged to the Company s nursing center business.

Discontinued Operations

Net operating losses for the divested Florida and Texas nursing centers increased to \$17 million in the second quarter of 2003 from \$4 million in the second quarter of 2002. For the six months ended June 30, 2003, net operating losses for the divested Florida and Texas nursing centers increased to \$30 million from \$7 million during the same period a year ago. The increases in operating losses in both periods were primarily attributable to growth in professional liability costs. Professional liability costs in the second quarter of 2003 approximated \$28 million compared to \$9 million in the second quarter of 2002. For the six months ended June 30, 2003, professional liability costs totaled \$50 million compared to \$18 million for the same period a year ago.

In connection with the Florida and Texas Divestiture, the Company recorded a pretax loss of \$59 million (\$36 million net of income taxes).

Florida and Texas Nursing Center Divestiture

In connection with the Florida and Texas Divestiture, the Company acquired 15 Florida nursing centers and one Texas nursing center from Ventas, Inc. (Ventas) (NYSE: VTR) on June 30, 2003 for approximately \$60 million and a \$4 million lease termination fee. In addition, the Company amended its master leases with Ventas to: (1) pay incremental rent in varying amounts generally over seven years, the net present value of which approximated \$44 million using a discount rate of 11%, (2) provide that all annual escalators under the master leases will be paid in cash at all times, and (3) expand certain cooperation and information sharing provisions of the master leases. The annual rent of approximately \$9 million on the acquired facilities terminated upon the closing of the purchase transaction. The Company financed its obligations at the closing of the purchase transaction through the use of existing cash.

For accounting purposes, the \$44 million present value rent obligation to Ventas was recorded as long-term debt in the Company s consolidated balance sheet.

The Company completed the divestiture of all of its Florida nursing center operations on June 30, 2003. The Company sold the real estate related to the 15 nursing centers it acquired from Ventas and the two nursing centers previously owned by the Company in Florida. The sale price for the real estate and related personal property associated with all of the Florida nursing center operations aggregated approximately \$64 million. The Company s consolidated balance sheet at June 30, 2003 included a \$61 million receivable from the sale of the Florida nursing centers because the Company did not receive these proceeds until July 1, 2003.

The Company also completed the sublease of the remaining Florida nursing center previously operated by the Company on June 30, 2003. The rental payments under the sublease approximate the Company s annual rental obligations under the existing lease agreement. The sublease will expire upon the expiration of the primary lease, whereupon the Company s obligation with respect to the primary lease also will terminate.

The Company also sold its accounts receivable relating to the Florida nursing centers.

The Company also completed the divestiture of its two Texas nursing center operations in the second quarter of 2003. The Company terminated the lease with respect to one facility and entered into a lease with a third party to transfer the operations of the other Texas facility acquired from Ventas. The Company also entered into a non-binding letter of intent to sell the remaining leased facility to the same third party.

Debt Reduction

Upon receipt of the sales proceeds from the Florida and Texas Divestiture, the Company completed the previously negotiated \$60 million repayment of its senior secured notes on July 1, 2003. After the repayment, the outstanding balance of the senior secured notes approximated \$100 million.

Tax Escrow Settlement

In April 2003, the Company received approximately \$14 million of previously escrowed tax refunds as a result of the favorable conclusion of certain federal income tax examinations for the 1996, 1997 and 1998 tax years that were shared with Ventas. The receipt of the \$14 million had no impact on the Company s second quarter earnings because fresh-start accounting rules adopted in connection with the Company s emergence from bankruptcy required that this transaction be recorded as a reduction of goodwill.

Second Quarter Commentary

During the second quarter, we made solid progress in executing our strategic operating plan, noted Edward L. Kuntz, Chairman and Chief Executive Officer of the Company. We successfully completed the divestiture of the Florida and Texas nursing centers, and our professional liability cost estimates related to the Company s continuing operations remained stable in connection with the regular quarterly independent

actuarial review. We also improved our liquidity during the quarter, increasing cash levels to \$170 million at the end of the quarter from \$100 million at March 31, 2003.

Appointment of Eddy J. Rogers, Jr. as Director

The Company also announced that it has expanded its Board of Directors by appointing Eddy J. Rogers, Jr., a partner with the Houston law firm of Andrews & Kurth, L.L.P., to the Board effective immediately.

We are pleased to have someone with Eddy's depth of experience join our Board. His extensive legal background and affiliation with other healthcare providers will be of significant assistance to the Board, commented Mr. Kuntz. Moreover, the addition of qualified independent directors to the Board further demonstrates our continuing commitment to sound corporate governance.

Mr. Rogers (age 62) has practiced law for over thirty years. He has substantial experience in various corporate matters including mergers and acquisitions, reorganizations, executive compensation, and shareholder disputes. Mr. Rogers received his undergraduate and J.D. degrees from Harvard University.

Mr. Rogers will serve on the Company s Audit and Compliance Committee and the Nominating and Governance Committee.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company s expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management and statements containing the words such as anticipate, approximate, believe, plan, estimate, project, could, should, will, intend, may and other similar expressions, are forward-looking statements.

expect,

Such forward-looking statements are inherently uncertain, and stockholders and other potential investors must recognize that actual results may differ materially from the Company s expectations as a result of a variety of factors, including, without limitation, those discussed below. Such forward-looking statements are based on management s current expectations and include known and unknown risks, uncertainties and other factors, many of which the Company is unable to predict or control, that may cause the Company s actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks, uncertainties and other factors detailed from time to time in the Company s filings with the Securities and Exchange Commission.

Factors that may affect the Company s plans or results include, without limitation, (a) the Company s ability to operate pursuant to the terms of its debt obligations and its master lease agreements with Ventas; (b) the Company s ability to meet its rental and debt service obligations; (c) adverse developments with respect to the Company s results of operations or liquidity; (d) the Company s ability to attract and retain key executives and other healthcare personnel; (e) increased operating costs due to shortages in qualified nurses and other healthcare personnel; (f) the effects of healthcare reform and government regulations, interpretation of regulations and changes in the nature and enforcement of regulations governing the healthcare industry; (g) changes in the reimbursement rates or methods of payment from third party payors, including the Medicare and Medicaid programs and the new prospective payment system for long-term acute care hospitals; (h) national and regional economic conditions, including their effect on the availability and cost of labor, materials and other services; (i) the Company s ability to control costs, particularly labor and employee benefit costs; (j) the Company s ability to comply with the terms of its Corporate Integrity Agreement; (k) the Company s ability to integrate operations of

acquired facilities; (1) the increase in the costs of defending and insuring against professional liability claims and the Company s ability to predict the estimated costs related to such claims, and (m) the Company s ability to successfully reduce (by divestiture or otherwise) its exposure to professional liability claims. Many of these factors are beyond the Company s control. The Company cautions investors that any forward-looking statements made by the Company are not guarantees of future performance. The Company disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

Kindred Healthcare, Inc. is a national provider of long-term healthcare services primarily operating nursing centers, hospitals and institutional pharmacies.

${\bf KINDRED\ HEALTHCARE, INC.}$

Financial Summary

(Unaudited)

(In thousands, except per share amounts)

	Three	e months ended June 30,		ths ended
	2003	2002	2003	2002
Revenues	\$ 839,2°	\$ 806,544	\$ 1,668,326	\$ 1,586,018
Income from continuing operations	\$ 9,70	01 \$ 27,391	\$ 9,558	\$ 48,646
Discontinued operations, net of income taxes: Loss from operations Loss on divestiture of operations	(17,1° (36,0°		(30,093) (36,019)	(6,806)
Net income (loss)	\$ (43,4.	30) \$ 23,662	\$ (56,554)	\$ 41,840
Earnings (loss) per common share: Basic:				
Income from continuing operations	\$ 0.5	56 \$ 1.58	\$ 0.55	\$ 2.81
Discontinued operations:	(0.4	00) (0.00)	(4.50)	(0.40)
Loss from operations Loss on divestiture of operations	(0.:		(1.73) (2.07)	(0.40)
Net income (loss)	\$ (2.4	49) \$ 1.36	\$ (3.25)	\$ 2.41
Diluted:				
Income from continuing operations	\$ 0	56 \$ 1.40	\$ 0.55	\$ 2.51
Discontinued operations:				
Loss from operations	(0.9		(1.73)	(0.35)
Loss on divestiture of operations	(2.	07)	(2.07)	
Net income (loss)	\$ (2.	49) \$ 1.21	\$ (3.25)	\$ 2.16
Shares used in computing earnings (loss) per common share:				
Basic	17,4	07 17,345	17,392	17,327
Diluted	17,4	14 19,554	17,399	19,332

Condensed Consolidated Statement of Operations

(Unaudited)

(In thousands, except per share amounts)

	Three months ended June 30,			Six months ended June 30,		
	2003	2002	2003	2002		
Revenues	\$ 839,218	\$ 806,544	\$ 1,668,326	\$ 1,586,018		
Salaries, wages and benefits	480,037	459,020	958,828	907,131		
Supplies	107,918	103,304	215,858	202,514		
Rent	66,586	64,866	131,991	127,596		
Other operating expenses	147,745	120,691	301,090	235,644		
Depreciation	20,358	17,249	40,188	33,790		
Interest expense	2,995	3,818	5,883	7,550		
Investment income	(1,676)	(3,396)	(3,311)	(5,275)		
			4 (50 505	1.500.050		
	823,963	765,552	1,650,527	1,508,950		
Income from continuing operations before reorganization items and income taxes Reorganization items	15,255	40,992 (5,520)	17,799	77,068 (5,520)		
Income from continuing operations before income taxes	15,255	46,512	17,799	82,588		
Provision for income taxes	5,554	19,121	8,241	33,942		
Income from continuing operations	9,701	27,391	9,558	48,646		
Discontinued operations, net of income taxes:						
Loss from operations	(17,112)	(3,729)	(30,093)	(6,806)		
Loss on divestiture of operations	(36,019)		(36,019)			
Net income (loss)	\$ (43,430)	\$ 23,662	\$ (56,554)	\$ 41,840		
Earnings (loss) per common share: Basic:						
Income from continuing operations	\$ 0.56	\$ 1.58	\$ 0.55	\$ 2.81		
Discontinued operations:						
Loss from operations	(0.98)	(0.22)	(1.73)	(0.40)		
Loss on divestiture of operations	(2.07)		(2.07)			
Net income (loss)	\$ (2.49)	\$ 1.36	\$ (3.25)	\$ 2.41		

Diluted:							
Income from continuing operations	\$ 0.56	\$	1.40	\$	0.55	\$	2.51
Discontinued operations:							
Loss from operations	(0.98)		(0.19)		(1.73)		(0.35)
Loss on divestiture of operations	(2.07)				(2.07)		
·	 						
Net income (loss)	\$ (2.49)	\$	1.21	\$	(3.25)	\$	2.16
		_		_		_	
Shares used in computing earnings (loss) per common share:							
Basic	17,407		17,345		17,392		17,327
Diluted	17,414		19,554		17,399		19,332

Condensed Consolidated Balance Sheet

(Unaudited)

(In thousands, except per share amounts)

Current asserts: Cash and cash equivalents \$170,137 \$244,070 Cash restricted 8,403 7,908 Insurance subsidiary investments 165,704 130,415 Accounts receivable less allowance for loss 384,173 420,611 Receivable from sale of assets 60,996 Inventories 29,608 30,460 Other 914,995 920,316 Property and equipment 626,841 611,944 Accumulated depreciation 153,955 (115,373) Accumulated depreciation 153,955 (115,373) Goodwill 77,353 88,259 Insurance subsidiary investments 33,549 18,171 Other 113,207 120,861 Due to third party payors 31,832 25,177 Current liabilities: 113,207 120,861 Due to third party payors 31,832 25,177 Other carcned liabilities 167,913 150,020 Long-term debt due within one year 4,144 258 Long-term debt due within one year 4,144 258 Deferred compensation 201,776 162,008 Profered credit and other liabilities 59,841 56,657 Courmon stock, \$0,25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,859 547,600 Capital in excess of par value 547,850 547,600 Capital in excess of par value 547,850 547,600 Capital in excess of par value 547,850 Capital in		June 30, 2003	December 31, 2002
Cash restricted 8.403 7.908 Insurance subsidiary investments 165,704 130,415 Accounts receivable less allowance for loss 384,173 420,611 Receivable from sale of assets 60,996 60,996 Inventories 29,680 30,460 Other 95,902 86,852 Property and equipment 626,841 611,944 Accoumulated depreciation (153,955) (153,373) Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 Current liabilities 113,207 120,861 Accounts payable \$1,661,990 \$1,644,178 Accounts payable \$124,470 \$124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258	ASSETS		
Cash restricted 8,403 7,908 Insurance subsidiary investments 165,704 130,415 Accounts receivable less allowance for loss 384,173 420,611 Receivable from sale of assets 60,996 10,406 Unventories 29,680 30,400 Other 95,902 86,852 Property and equipment 626,841 611,944 Accumulated depreciation (153,955) (115,373) Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 Current liabilities 81,661,990 \$ 1,644,178 Current liabilities 220,951 220,151 Accounts payable \$ 124,470 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,141 258<	Current assets:		
Insurance subsidiary investments 165,704 130,415 362,011 362,011 362,011 362,011 362,011 362,011 362,011 362,001 362,001 362,001 362,001 362,002 368,002 362,002 <t< td=""><td>Cash and cash equivalents</td><td>\$ 170,137</td><td>\$ 244,070</td></t<>	Cash and cash equivalents	\$ 170,137	\$ 244,070
Accounts receivable from sale of assets 60,996 10,996 30,460 Other 20,680 30,460 Other 95,902 86,852 86,852 Section of the sec	Cash restricted	8,403	7,908
Receivable from sale of assets 60,996 10,400<	Insurance subsidiary investments	165,704	130,415
Property and equipment 626,841 611,944 Accumulated depreciation 153,955 (115,373) (153,955) (115,373) (153,955) (115,373) (153,955) (115,373) (153,955) (115,373) (115,3	Accounts receivable less allowance for loss		420,611
Other 95,902 86,852 Property and equipment 626,841 611,944 Accumulated depreciation 153,955 (115,373) Goodwill 77,353 88,259 Insurance subsidiary investments 33,549 18,171 Other 113,207 120,861 *** LIABILITIES AND STOCKHOLDERS EQUITY** *** Current liabilities: *** LIABILITIES AND STOCKHOLDERS EQUITY** *** Accounts payable \$ 124,470 \$ 124,466 Salaries, wages and other compensation 20,951 220,124 *** Due to third party payors 31,832 25,177 *** Due to third party payors 31,832 25,177 *** Due to third party payors 31,832 25,172 *** Due to third p	Receivable from sale of assets	60,996	
Property and equipment	Inventories		
Property and equipment 626,841 (511,944) 611,944 Accumulated depreciation (153,955) (115,373) (115,373) Goodwill 77,353 (88,259) 88,259 Insurance subsidiary investments 83,549 (18,171) 18,171 Other \$1,661,990 (13,207) \$1,644,178 ***********************************	Other	95,902	86,852
Property and equipment 626,841 (511,944) 611,944 Accumulated depreciation (153,955) (115,373) (115,373) Goodwill 77,353 (88,259) 88,259 Insurance subsidiary investments 83,549 (18,171) 18,171 Other \$1,661,990 (13,207) \$1,644,178 ***********************************			
Property and equipment 626,841 (511,944) 611,944 Accumulated depreciation (153,955) (115,373) (115,373) Goodwill 77,353 (88,259) 88,259 Insurance subsidiary investments 83,549 (18,171) 18,171 Other \$1,661,990 (13,207) \$1,644,178 ***********************************		914,995	920,316
Accumulated depreciation (153,955) (115,373) 472,886 496,571 Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 **** LIABILITIES AND STOCKHOLDERS EQUITY** **** Current liabilities** Accounts payable \$124,470 \$124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0,25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,609 547,609		, and the second	,
Accumulated depreciation (153,955) (115,373) 472,886 496,571 Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 **** LIABILITIES AND STOCKHOLDERS EQUITY** **** Current liabilities** Accounts payable \$124,470 \$124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0,25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,609 547,609	Property and equipment	626.841	611.944
Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 *** Insurance subsidiary investments \$1,661,990 \$1,644,178 *** Insurance subsidiary investments \$1,661,990 \$1,644,178 *** Insurance subsidiary investments \$1,661,990 \$1,644,178 *** Current labilities *** Current liabilities Accounts payable \$124,470 \$124,466 Salaries, wages and other compensation 220,951 220,124 Other accrued liabilities 1167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 206,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0,25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Appital in excess of par value 547,600			
Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 ***********************************			
Goodwill 77,353 88,259 Insurance subsidiary investments 83,549 18,171 Other 113,207 120,861 ***********************************		172 886	406 571
Ray		472,000	450,571
Ray	Goodwill	77 353	99.250
Other 113,207 120,861 \$1,661,990 \$1,644,178 Current liabilities: Accounts payable \$124,470 \$124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt due within one year 562,674 582,156 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0,25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
\$1,661,990 \$ 1,644,178 LIABILITIES AND STOCKHOLDERS EQUITY Current liabilities: Accounts payable \$124,470 \$124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt due within one year 562,674 582,156 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	•		
LIABILITIES AND STOCKHOLDERS EQUITY Current liabilities: Accounts payable \$ 124,470 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	Oulci		120,001
LIABILITIES AND STOCKHOLDERS EQUITY Current liabilities: Accounts payable \$ 124,470 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609		ф 1 <i>СС</i> 1 000	Φ 1 (44 170
Current liabilities: Accounts payable \$ 124,470 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,609		\$ 1,661,990	\$ 1,644,178
Current liabilities: Accounts payable \$ 124,476 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,609			
Current liabilities: Accounts payable \$ 124,476 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,609			
Accounts payable \$ 124,476 \$ 124,466 Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	LIABILITIES AND STOCKHOLDERS EQUITY		
Salaries, wages and other compensation 220,951 220,124 Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
Due to third party payors 31,832 25,177 Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
Other accrued liabilities 167,913 150,020 Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 562,674 582,156 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
Income taxes 13,364 62,111 Long-term debt due within one year 4,144 258 Long-term debt 562,674 582,156 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	* * * *		
Long-term debt due within one year 4,144 258 562,674 582,156 Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: 50,25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609		·	
Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	Long-term debt due within one year	4,144	258
Long-term debt 201,776 162,008 Professional liability risks 260,528 211,771 Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
Professional liability risks Deferred credits and other liabilities Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares Capital in excess of par value 547,609		562,674	582,156
Professional liability risks Deferred credits and other liabilities Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares Capital in excess of par value 547,609			
Deferred credits and other liabilities 59,841 56,615 Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	Long-term debt	201,776	162,008
Stockholders equity: Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares Capital in excess of par value 547,609	Professional liability risks	260,528	211,771
Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	Deferred credits and other liabilities	59,841	56,615
Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609			
Common stock, \$0.25 par value; authorized 175,000 shares; issued 17,649 shares 4,412 4,412 Capital in excess of par value 547,459 547,609	Stockholders equity:		
Capital in excess of par value 547,459 547,609		4,412	4,412
		(4,585)	(6,967)

Accumulated other comprehensive income Retained earnings	325 29,560	460 86,114
	577,171	631,628
	\$ 1,661,990	\$ 1,644,178
	<u>. , , , </u>	

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(In thousands)

	Three months ended		Six months ended		
	June 30,		June	30,	
	2003	2002	2003	2002	
Cash flows from operating activities:		' <u> </u>			
Net income (loss)	\$ (43,430)	\$ 23,662	\$ (56,554)	\$ 41,840	
Adjustments to reconcile net income (loss) to net cash provided by operating	ψ (43,430)	Ψ 23,002	ψ (50,554)	Ψ 11,010	
activities:					
Depreciation	20,526	17,413	40,609	34,109	
Amortization of deferred compensation costs	984	1,320	2,237	3,906	
Provision for doubtful accounts	6,678	3,217	12,966	7,501	
Loss on divestiture of discontinued operations	36,019	5,217	36,019	7,001	
Unusual transactions	20,025	525	00,025	525	
Reorganization items		(5,520)		(5,520)	
Other	910	550	1,416	605	
Change in operating assets and liabilities:	710	230	1,.10	005	
Accounts receivable	64,373	(4,147)	11,057	(3,548)	
Inventories and other assets	13,193	20,057	6,806	3,066	
Accounts payable	1,202	(8,352)	(1,796)	7,175	
Income taxes	(7,259)	1,582	(12,716)	5,889	
Due to third party payors	3,104	382	6,655	(7,022)	
Other accrued liabilities	48,753	42,754	77,083	40,076	
other accrace natifices					
N-4 h i d h i i	145.052	02 442	102 702	129 602	
Net cash provided by operating activities before reorganization items Payment of reorganization items	145,053	93,443	123,782	128,602	
Payment of reorganization items	(522)	(1,214)	(917)	(3,676)	
Net cash provided by operating activities	144,531	92,229	122,865	124,926	
Cash flows from investing activities:					
Purchase of property and equipment	(17,477)	(19,359)	(28,042)	(29,227)	
Acquisition of healthcare facilities	(63,795)	(45,551)	(63,795)	(45,551)	
Sale of assets	7,659	752	7,659	752	
Surety bond deposits		9,676		9,676	
Net change in insurance subsidiary investments	(694)	(35,112)	(100,667)	(34,204)	
Net change in other investments	2,645	1,935	(2,040)	2,691	
Other	(1,702)	42	(2,035)	201	
Net cash used in investing activities	(73,364)	(87,617)	(188,920)	(95,662)	
Cash flows from financing activities:					
Repayment of long-term debt	(116)	(178)	(228)	(279)	
Payment of deferred financing costs	(1,276)	(1,010)	(2,872)	(1,010)	
Other	189	(2,018)	(4,778)	(6,512)	
Net cash used in financing activities	(1,203)	(3,206)	(7,878)	(7,801)	

Change in cash and cash equivalents	69,964	1,406	(73,933)	21,463
Cash and cash equivalents at beginning of period	100,173	210,856	244,070	190,799
	A 450 435	A 212 262	A 450 405	A 212 262
Cash and cash equivalents at end of period	\$ 170,137	\$ 212,262	\$ 170,137	\$ 212,262

${\bf KINDRED\ HEALTHCARE, INC.}$

Condensed Business Segment Data

(Unaudited)

(In thousands)

	Three months ended June 30,		Six month	hs ended
			June 30, (a)	
	2003	2002 (a)	2003	2002
Revenues:				
Health services division:				
Nursing centers	\$ 431,207	\$ 427,136	\$ 856,114	\$ 855,353
Rehabilitation services	8,795	8,566	17,297	16,396
	440,002	435,702	873,411	871,749
Hospital division:				
Hospitals	346,054	322,764	686,909	619,206
Ancillary services	1,484	2,278	3,243	4,148
	347,538	325,042	690,152	623,354
Pharmacy division	67,136	59,948	135,964	119,126
	854,676	820,692	1,699,527	1,614,229
Elimination of pharmacy charges to Company nursing centers	(15,458)	(14,148)	(31,201)	(28,211)
Emilination of pharmacy charges to Company hursing centers	(13,436)	(14,146)	(31,201)	(20,211)
	\$ 839,218	\$ 806,544	\$ 1,668,326	\$ 1,586,018
Income from continuing operations:				
Operating income (loss):				
Health services division:				
Nursing centers	\$ 56,465	\$ 85,774	\$ 98,390	\$ 170,469
Rehabilitation services	(750)	288	(1,709)	222
	55,715	86,062	96,681	170,691
Hospital division:				
Hospitals	74,017	62,326	144,321	121,900
Ancillary services	(562)	246	(382)	381
	73,455	62,572	143,939	122,281
Pharmacy division	6,109	5,823	13,011	11,360
Corporate overhead	(31,761)	(30,403)	(61,081)	(63,078)
	103,518	124,054	192,550	241,254
Unusual transactions		(525)		(525)
Reorganization items		5,520		5,520
Operating income	103,518	129,049	192,550	246,249
Rent	(66,586)	(64,866)	(131,991)	(127,596)

Depreciation	(20,358)	(17,249)	(40,188)	(33,790)
Interest, net	(1,319)	(422)	(2,572)	(2,275)
Income from continuing operations before income taxes	15,255	46,512	17,799	82,588
Provision for income taxes	5,554	19,121	8,241	33,942
	\$ 9,701	\$ 27,391	\$ 9,558	\$ 48,646

(a) Certain prior period amounts have been reclassified to conform with the current year presentation.

Condensed Business Segment Data (Continued)

(Unaudited)

(In thousands)

	Three mo	Three months ended		ths ended
	Jun	June 30,		30, (a)
	2003	2002 (a)	2003	2002
Rent:				
Health services division:				
Nursing centers	\$ 40,956	\$ 39,136	\$ 81,098	\$ 77,531
Rehabilitation services	95	24	164	48
	41,051	39,160	81,262	77,579
Hospital division:				
Hospitals	24,625	24,675	48,829	48,011
Ancillary services	213	234	414	459
	24,838	24,909	49,243	48,470
Pharmacy division	638	734	1,363	1,451
Corporate	59	63	123	96
	\$ 66,586	\$ 64,866	\$ 131,991	\$ 127,596
Depreciation:				
Health services division:	Φ (010	Φ 5.005	ф. 12.40 2	Φ 11 000
Nursing centers	\$ 6,818	\$ 5,985	\$ 13,492	\$ 11,906
Rehabilitation services		6		15
	6,838	5,991	13,528	11,921
Hospital division:				
Hospitals	7,658	6,638	14,913	12,999
Ancillary services	(39)	200	80	346
	7,619	6,838	14,993	13,345
Pharmacy division	552	428	1,083	825
Corporate	5,349	3,992	10,584	7,699
	\$ 20,358	\$ 17,249	\$ 40,188	\$ 33,790
	———	Ψ 17,219	Ψ 10,100	Ψ 20,770
Capital expenditures, excluding acquisitions:				
Health services division (including discontinued operations)	\$ 6,422	\$ 4,728	\$ 9,695	\$ 6,844
Hospital division	4,133	6,430	6,955	9,746
Pharmacy division	522	782	1,138	1,178
Corporate:				
Information systems	5,992	6,632	9,199	9,962
Other	408	787	1,055	1,497

\$ 17,477 \$ 19,359	\$ 28,042	\$ 29,227
----------------------------	-----------	-----------

Certain prior period amounts have been reclassified to conform with the current year presentation.

(a)

Condensed Business Segment Data (Continued)

(Unaudited)

	Three mo	Six months ended			
	Jun	e 30,	June	30, (a)	
	2003	2002 (a)	2003	2002	
Nursing Center Data:					
End of period data:					
Number of nursing centers:					
Owned or leased	258	258			
Managed	7	10			
	265	268			
Number of licensed beds:					
Owned or leased	33,394	33,634			
Managed	803	1,017			
	34,197	34,651			
Revenue mix %:					
Medicare	33	34	33	34	
Medicaid	48	47	48	47	
Private and other	19	19	19	19	
Patient days (excludes managed facilities):					
Medicare	411,289	404,048	822,385	807,948	
Medicaid	1,765,407	1,773,717	3,520,443	3,542,989	
Private and other	432,200	462,196	856,938	925,541	
	2,608,896	2,639,961	5,199,766	5,276,478	
Revenues per patient day:					
Medicare	\$ 342	\$ 358	\$ 340	\$ 358	
Medicaid	118	112	118	113	
Private and other	190	180	189	181	
Weighted average	165	162	165	162	
Average daily census	28,669	29,011	28,728	29,152	
Occupancy %	85.1	85.7	85.3	85.9	
Hospital Data:					
End of period data:					
Number of hospitals	65	63			
Number of licensed beds	5,430	5,276			
Revenue mix %:					
Medicare	59	61	60	59	

Medicaid	8		8	8		9
Private and other	33		31	32		32
Patient days:						
Medicare	220,123	218,	392	443,042		414,449
Medicaid	33,218	32,	635	65,484		66,499
Private and other	61,136	57,	266	119,505		115,703
	 			 	_	
	314,477	308,	293	628,031		596,651
			_		_	
Revenues per patient day:						
Medicare	\$ 936	\$	893	\$ 927	\$	887
Medicaid	824		811	824		846
Private and other	1,843	1,	768	1,860		1,688
Weighted average	1,100	1,	047	1,094		1,038
Average daily census	3,456	3,	388	3,470		3,296
Occupancy %	66.4	(55.9	66.9		66.7
Pharmacy Data:						
Number of customer licensed beds at end of period:						
Company-operated	27,566	30,	568			
Non-affiliated	28,848	27,	148			
	56,414	57,	716			

⁽a) Certain prior period amounts have been reclassified to conform with the current year presentation.

Condensed Consolidated Statement of Operations

(Unaudited)

(In thousands, except per share amounts)

		2002 Qu		2003 Quarters			
	First	Second	Third (b)	Fourth	First (a)	Second	
Revenues	\$ 779,474	\$ 806,544	\$ 827,141	\$ 816,344	\$ 829,108	\$ 839,218	
Salaries, wages and benefits	448,111	459,020	467,276	468,522	478,791	480,037	
Supplies	99,210	103,304	106,113	106,898	107,940	107,918	
Rent	62,730	64,866	65,357	65,838	65,405	66,586	
Other operating expenses	114,953	120,691	145,079	128,681	153,345	147,745	
Depreciation	16,541	17,249	18,052	18,735	19,830	20,358	
Interest expense	3,732	3,818	1,368	3,135	2,888	2,995	
Investment income	(1,879)	(3,396)	(2,343)	(2,050)	(1,635)	(1,676)	
	743,398	765,552	800,902	789,759	826,564	823,963	
Income from continuing operations before							
reorganization items and income taxes	36,076	40,992	26,239	26,585	2,544	15,255	
Reorganization items	30,070	(5,520)	20,237	20,303	2,544	13,233	
Reorganization tenis		(3,320)					
Income from continuing operations before income							
taxes	36,076	46,512	26,239	26,585	2,544	15,255	
Provision for income taxes	14,821	19,121	12,159	10,661	2,687	5,554	
Income (loss) from continuing operations	21,255	27,391	14,080	15,924	(143)	9,701	
Discontinued operations, net of income taxes:							
Loss from operations	(3,077)	(3,729)	(24,236)	(12,855)	(12,981)	(17,112)	
Loss on divestiture of operations						(36,019)	
Net income (loss)	\$ 18,178	\$ 23,662	\$ (10,156)	\$ 3,069	\$ (13,124)	\$ (43,430)	
Earnings (loss) per common share: Basic:							
Income (loss) from continuing operations	\$ 1.23	\$ 1.58	\$ 0.81	\$ 0.92	\$ (0.01)	\$ 0.56	
Discontinued operations:	Ψ 1.23	Ψ 1.50	ψ 0.01	Ψ 0.72	ψ (0.01)	φ 0.50	
Loss from operations	(0.18)	(0.22)	(1.39)	(0.74)	(0.75)	(0.98)	
Loss on divestiture of operations	(0.10)	(0.22)	(1.57)	(0.74)	(0.73)	(2.07)	
Loss on divestitute of operations						(2.07)	
Net income (loss)	\$ 1.05	\$ 1.36	\$ (0.58)	\$ 0.18	\$ (0.76)	\$ (2.49)	
Diluted:							
Income (loss) from continuing operations	\$ 1.11	\$ 1.40	\$ 0.77	\$ 0.92	\$ (0.01)	\$ 0.56	
Discontinued operations:							
Loss from operations	(0.16)	(0.19)	(1.32)	(0.74)	(0.75)	(0.98)	
Loss on divestiture of operations						(2.07)	

	_				_						_	
Net income (loss)	\$	0.95	\$	1.21	\$	(0.55)	\$	0.18	\$	(0.76)	\$	(2.49)
	_		_		_		_		_		_	
Shares used in computing earnings (loss) per common												
share:												
Basic		17,308		17,345		17,380		17,377		17,377		17,407
Diluted		19,074		19,554		18,395(c)		17,384		17,377		17,414

⁽a) Prior period results of operations have been restated in accordance with Statement of Financial Accounting Standards (SFAS) No. 144 (SFAS 144), Accounting for the Impairment or Disposal of Long-Lived Assets, to reflect the classification of the Florida and Texas nursing centers as discontinued operations.

⁽b) In accordance with SFAS No. 145 (SFAS 145), Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections, a \$2.3 million pretax gain on the extinguishment of debt previously classified as an extraordinary item was reclassified to interest expense.

⁽c) Prior period diluted shares used in computing earnings (loss) per common share have been restated to reflect the dilutive effect of warrants, stock options and non-vested restricted stock after restating the results of operations in accordance with SFAS 144.

${\bf KINDRED\ HEALTHCARE, INC.}$

Condensed Business Segment Data

(Unaudited)

(In thousands)

		2002 Quar	2003 Quarters			
	First	Second	Third (c)	Fourth	First (a)	Second
Revenues:						
Health services division:						
Nursing centers	\$ 428,217	\$ 427,136	\$ 436,329	\$ 426,886	\$ 424,907	\$ 431,207
Rehabilitation services	7,830	8,566	8,697	9,203	8,502	8,795
	436,047	435,702	445,026	436,089	433,409	440,002
Hospital division:						
Hospitals	296,442	322,764	330,910	326,183	340,855	346,054
Ancillary services	1,870	2,278	1,639	1,766	1,759	1,484
	298,312	325,042	332,549	327,949	342,614	347,538
Pharmacy division	59,178	59,948	64,014	67,089	68,828	67,136
	793,537	820,692	841,589	831,127	844,851	854,676
Elimination of pharmacy charges to Company nursing centers	(14,063)	(14,148)	(14,448)	(14,783)	(15,743)	(15,458)
	\$ 779,474	\$ 806,544	\$ 827,141	\$ 816,344	\$ 829,108	\$ 839,218
Income (loss) from continuing operations:						
Operating income (loss): Health services division:						
	¢ 94.605	¢ 05 774	¢ 62.490	¢ 50.206	¢ 41.025	¢ 56.165
Nursing centers Rehabilitation services	\$ 84,695	\$ 85,774 288	\$ 63,480 1,155	\$ 59,396 (1,639)	\$ 41,925 (959)	\$ 56,465 (750)
Renadifitation services	(00)	200	1,133	(1,039)	(939)	(730)
	94.620	96.062	(4.625	E7 7E7	40.066	EE 715
Hasnital divisions	84,629	86,062	64,635	57,757	40,966	55,715
Hospital division: Hospitals	59,574	62,326	70,979	67,561	70,304	74,017
Ancillary services	135	246	(240)	118	180	(562)
Thomas services			(210)			(302)
	59,709	62,572	70,739	67,679	70,484	73,455
Pharmacy division	5,537	5,823	5,856	6,056	6,902	6,109
Corporate overhead	(32,675)	(30,403)	(32,557)	(21,569)	(29,320)	(31,761)
	117,200	124,054	108,673	109,923	89,032	103,518
Unusual transactions		(525)		2,320		
Reorganization items		5,520				
Operating income	117,200	129,049	108,673	112,243	89,032	103,518
Rent	(62,730)	(64,866)	(65,357)	(65,838)	(65,405)	(66,586)
Depreciation	(16,541)	(17,249)	(18,052)	(18,735)	(19,830)	(20,358)
Interest, net	(1,853)	(422)	975	(1,085)	(1,253)	(1,319)

Income from continuing operations before income taxes Provision for income taxes	36,076	46,512	26,239	26,585	2,544	15,255
	14,821	19,121	12,159	10,661	2,687	5,554
	\$ 21,255	\$ 27,391	\$ 14,080	\$ 15,924	\$ (143)	\$ 9,701

⁽a) Prior period results of operations have been restated in accordance with SFAS 144 to reflect the classification of the Florida and Texas nursing centers as discontinued operations.

⁽b) Operating data for 2002 have been reclassified to reflect certain cost realignments between the nursing centers and rehabilitation services business and the establishment of the Company s institutional pharmacy business as a separate operating division, both of which were effective on January 1, 2003.

⁽c) In accordance with SFAS 145, a \$2.3 million pretax gain on the extinguishment of debt previously classified as an extraordinary item was reclassified to interest expense.

Condensed Business Segment Data (Continued)

(Unaudited)

(In thousands)

		2003 Quarters				
	First	Second	Third	Fourth	First (a)	Second
Rent:						
Health services division:						
Nursing centers	\$ 38,395	\$ 39,136	\$ 39,789	\$ 40,124	\$ 40,142	\$ 40,956
Rehabilitation services	24	24	37	43	69	95
	38,419	39,160	39,826	40,167	40,211	41,051
Hospital division:						
Hospitals	23,336	24,675	24,513	24,375	24,204	24,625
Ancillary services	225	234	225	232	201	213
	23,561	24,909	24,738	24,607	24,405	24,838
Pharmacy division	717	734	741	998	725	638
Corporate	33	63	52	66	64	59
	\$ 62,730	\$ 64,866	\$ 65,357	\$ 65,838	\$ 65,405	\$ 66.586
	Ψ 02,730	Ψ 0 1,000	ψ 03,337	ψ 03,030	ψ 03, 103	Ψ 00,300
Depreciation:						
Health services division:						
Nursing centers	\$ 5,921	\$ 5,985	\$ 6,363	\$ 6,392	\$ 6,674	\$ 6,818
Rehabilitation services	9	6	13	15	16	20
	5,930	5,991	6,376	6,407	6,690	6,838
Hospital division:						
Hospitals	6,361	6,638	6,994	7,087	7,255	7,658
Ancillary services	146	200	131	103	119	(39)
	6,507	6,838	7,125	7,190	7,374	7,619
Pharmacy division	397	428	469	513	531	552
Corporate	3,707	3,992	4,082	4,625	5,235	5,349
	\$ 16,541	\$ 17,249	\$ 18,052	\$ 18,735	\$ 19,830	\$ 20,358
Capital expenditures, excluding acquisitions:						
Health services division (including discontinued operations)	\$ 2,116	\$ 4,728	\$ 6,498	\$ 10,785	\$ 3,273	\$ 6,422
Hospital division	3,316	6,430	6,056	10,831	2,822	4,133
Pharmacy division	396	782	882	1,431	616	522
Corporate:						
Information systems	3,330	6,632	6,474	9,140	3,207	5,992
Other	710	787	1,056	1,691	647	408
	\$ 9,868	\$ 19,359	\$ 20,966	\$ 33,878	\$ 10,565	\$ 17,477

- (a) Prior period results of operations have been restated in accordance with SFAS 144 to reflect the classification of the Florida and Texas nursing centers as discontinued operations, unless otherwise indicated.
- (b) Operating data for 2002 have been reclassified to reflect certain cost realignments between the nursing centers and rehabilitation services business and the establishment of the Company s institutional pharmacy business as a separate operating division, both of which were effective on January 1, 2003.

${\bf KINDRED\ HEALTHCARE, INC.}$

Condensed Business Segment Data (Continued)

(Unaudited)

				2002 Qu	arters (a)			2003 Quarters			
	F	irst	s	econd	-	Third	F	ourth	Fir	rst (a)	s	Second
Nursing Center Data:												
End of period data:												
Number of nursing centers:												
Owned or leased		260		258		258		258		258		258
Managed		14		10		10		7		7		7
		274		268		268		265		265		265
Number of licensed beds:											_	
Owned or leased		33,699		33,634		33,606		33,587		33,563		33,394
Managed		1,417		1,017		1,017		803		803		803
	_	35,116		34,651		34,623		34,390		34,366	_	34,197
	_	33,110		34,031	_	34,023		34,390	_	34,300	_	34,197
Revenue mix %:												
Medicare		34		34		33		31		33		33
Medicaid		46		47		48		50		48		48
Private and other		20		19		19		19		19		19
Patients days (excludes managed facilities):												
Medicare	4	03,900		404,048		394,446		389,018	4	111,096		411,289
Medicaid	1,7	69,272	1,	773,717	1,	814,270	1,	820,422	1,7	755,036	1.	,765,407
Private and other	4	63,345		462,196		461,289		452,894		124,738		432,200
	2,6	36,517	2,639,961		2,	2,670,005		2,662,334		2,590,870		,608,896
			_		_		_		_		_	
Revenues per patient day:	Φ.	250	Φ.	250	Φ.	261	Φ.	22.4	Φ.	225	Φ.	2.42
Medicare	\$	359	\$	358	\$	361	\$	334	\$	337	\$	342
Medicaid		113		112		115		118		117		118
Private and other Weighted average		181 162		180 162		183 163		183 160		189 164		190 165
Hospital Data:												
End of period data:												
Number of hospitals		57		63		64		65		65		65
Number of licensed beds		4,961		5,276		5,344		5,385		5,408		5,430
Revenue mix % (b):												
Medicare		58		61		58		61		60		59
Medicaid		10		8		8		9		8		8
Private and other		32		31		34		30		32		33
Patients days:												
Medicare		96,057		218,392		209,158		211,990	2	222,919		220,123
Medicaid		33,864		32,635		33,590		34,733		32,266		33,218

Edgar Filing: KINDRED HEALTHCARE INC - Form 8-K

Private and other	58,437		57,266		56,623			57,279		58,369		61,136
											-	
		288,358		308,293		299,371		304,002	313,554			314,477
	_		_		_		_		_		_	
Revenues per patient day (b):												
Medicare	\$	880	\$	893	\$	913	\$	940	\$	918	\$	936
Medicaid		880		811		831		821		825		824
Private and other		1,609		1,768		1,977		1,719		1,877		1,843
Weighted average		1,028		1,047		1,105		1,073		1,087		1,100
Pharmacy Data:												
Number of customer licensed beds at												
end of period:												
Company-operated		30,471		30,568		30,279		29,966		29,804		27,566
Non-affiliated		25,695		27,148		28,460		28,873		28,365		28,848
			_		_		_		_		_	
		56,166		57,716		58,739		58,839		58,169		56,414

⁽a) Prior period results of operations have been restated in accordance with SFAS 144 to reflect the classification of the Florida and Texas nursing centers as discontinued operations.

⁽b) Includes \$12.1 million related to a favorable settlement with a private insurance company recorded in the third quarter of 2002.